Sepsis, a life-threatening condition, claims over 11 million lives annually, primarily due to biphasic immune dysregulation. This dysregulation manifests as an initial cytokine storm followed by immune paralysis, which traditional biomarkers and treatments fail to address effectively. But here's where it gets controversial: exosomes, tiny extracellular vesicles, exhibit a dual role in sepsis, acting as both pathological mediators and potential therapeutic tools. Early on, they amplify inflammation, while in the late stage, they may offer protective effects. This paradoxical nature sparks debate: can we harness exosomes to treat sepsis, or will their pathogenic role outweigh the benefits? And this is the part most people miss: exosomes act as systemic 'signaling hubs,' connecting organ dysfunction and propagating injury signals between tissues, transforming local infection into systemic sepsis. Their ability to modulate immune responses and deliver therapeutic cargo makes them a promising yet complex intervention. However, challenges like inconsistent isolation methods, patient heterogeneity, and translational hurdles persist. As we explore engineered exosomes and their potential, one question lingers: can we unlock their therapeutic promise while mitigating their pathogenic effects? The answer may lie in understanding their context-dependent nature and optimizing their production and delivery, paving the way for personalized sepsis treatments.
